Magnesium inhibits wnt/b-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  De Oca, Addy Montes ^a,b   Guerrero, Fatima ^a,b   Martinez Moreno, Julio M ^a   Madueño, Juan A ^a   Herencia, Carmen ^a   Peralta, Alan ^b   Almaden, Yolanda ^a   Lopez, Ignacio ^b   Aguilera Tejero, Escolastico ^b   Gundlach, Kristina ^c   Büchel, Janine ^c   Peter, Mirjam E ^c   Passlick Deetjen, Jutta ^d   Rodriguez, Mariano ^a   Muñoz Castañeda, Juan R ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c FRESENIUS MEDICAL CARE   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOETHOXYDIPHENYLBORANE; BETA CATENIN; MAGNESIUM; OSTEOCALCIN; OSTEOPROTEGERIN; OSTERIX; PHOSPHATE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CALCIFICATION; CELL NUCLEUS; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DKK 1 GENE; DOWN REGULATION; FRIZZLED 3 GENE; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRPM7 GENE; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 84896084795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089525     Document Type: Article

References (49)

1. Block GA, Port FK (2000) Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 1226-1237. (Pubitemid 30354431)
2. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68: 429-436. doi:10.1111/j.1523-1755.2005.00421.x. (Pubitemid 43323098)
3. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H (2005) Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96: 717-722. doi:10.1161/01.RES.0000161997.24797.c0. (Pubitemid 40559510)
4. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, et al. (2011) Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305: 1119-1127. doi:10.1001/jama.2011. 308.
5. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, et al. (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-17.
6. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, et al. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824. doi:10.1111/j.1523-1755.2005. 00600.x. (Pubitemid 43169927)
7. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, et al. (2009) Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20: 388-396. doi:10.1681/ASN.2008060609.
8. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, et al. (2008) A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51: 952-965. doi:10.1053/j.ajkd.2008.02.298. (Pubitemid 351697566)
9. De Francisco ALM, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, et al. (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25: 3707-3717. doi:10.1093/ndt/gfq292.
10. Mohammed I, Hutchison AJ (2009) Oral phosphate binders for the management of serum phosphate levels in dialysis patients. J Ren Care 35 Suppl 1: 65-70. doi:10.1111/j.1755-6686.2009.00052.x.
11. Spiegel DM, Farmer B, Smits G, Chonchol M (2007) Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr 17: 416-422. doi:10.1053/j.jrn.2007.08.005. (Pubitemid 350001351)
12. Spiegel DM, Farmer B (2009) Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int 13: 453-459. doi:10.1111/j.1542-4758.2009.00364.x.
13. Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, et al. (2007) Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68: 222-227. (Pubitemid 47527442)
14. Navarro-González JF, Mora-Fernández C, García- Pérez J (2009) Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 22: 37-44. doi:10.1111/j.1525-139X.2008.00530.x.
15. Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, et al. (2012) Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 27: 514-521. doi:10.1093/ndt/ gfr321.
16. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA (2013) Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 28: 869-878. doi:10.1093/ndt/ gfs520.
17. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, et al. (2010) Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56: 453-462. doi:10.1161/ HYPERTENSIONAHA.110.152058.
18. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, et al. (2012) Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 35: 31-39. doi:10.1159/000334742.
19. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, et al. (2013) Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83: 1109-1117. doi:10.1038/ki.2013.34.
20. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, et al. (2008) Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40: 1075-1082. doi:10.1007/s11255-008-9410-3.
21. Ennever J, Vogel JJ (1981) Magnesium inhibition of apatite nucleation by proteolipid. J Dent Res 60: 838-841.
22. Cheng S-L, Shao J-S, Halstead LR, Distelhorst K, Sierra O, et al. (2010) Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res 107: 271-282. doi:10.1161/CIRCRESAHA.110.219899.
23. Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M (2008) Extracellular transglutaminase 2 activates beta-catenin signaling in calcifying vascular smooth muscle cells. FEBS Lett 582: 1552-1557. doi:10.1016/j.febslet.2008.03. 053.
24. Komori T (2011) Signaling networks in RUNX2-dependent bone development. J Cell Biochem 112: 750-755. doi:10.1002/jcb.22994.
25. Mikhaylova L, Malmquist J, Nurminskaya M (2007) Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a. Calcif Tissue Int 81: 372-381. doi:10.1007/s00223-007-9073-6. (Pubitemid 50000811)
26. Shao J-S, Cheng S-L, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, et al. (2005) Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115: 1210-1220. doi:10.1172/JCI24140. (Pubitemid 40629039)
27. Martínez-Moreno JM, Muñoz-Castañeda JR, Herencia C, Oca AM de, Estepa JC, et al. (2012) In vascular smooth muscle cells paricalcitol prevents phosphateinduced Wnt/b-catenin activation. Am J Physiol Renal Physiol 303: F1136-1144. doi:10.1152/ajprenal.00684.2011.
28. Engelse MA, Neele JM, Bronckers AL, Pannekoek H, de Vries CJ (2001) Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res 52: 281-289. (Pubitemid 33000405)
29. Van Campenhout A, Golledge J (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204: 321-329. doi:10.1016/j.atherosclerosis.2008.09.033.
30. Li X, Yang H-Y, Giachelli CM (2006) Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98: 905-912. doi:10.1161/01.RES.0000216409.20863.e7.
31. Li X, Yang H-Y, Giachelli CM (2008) BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 199: 271-277. doi:10.1016/j.atherosclerosis.2007.11.031.
32. Montes de Oca A, Madueño JA, Martinez-Moreno JM, Guerrero F, Muñoz-Castañeda J, et al. (2010) High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. Journal of Bone and Mineral Research 25: 1996-2005. doi:10.1002/jbmr.93.
33. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, et al. (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89: 1147-1154. (Pubitemid 34627872)
34. Taylor J, Butcher M, Zeadin M, Politano A, Shaughnessy SG (2011) Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. J Cell Biochem 112: 581-588. doi:10.1002/jcb.22948.
35. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, et al. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192: 463-474. (Pubitemid 30666247)
36. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, et al. (2006) TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 203: 239-250. doi:10.1084/jem.20051062. (Pubitemid 43139661)
37. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, et al. (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857-2867. doi:10.1097/01.ASN.0000141960.01035.28. (Pubitemid 41103395)
38. Son B-K, Akishita M, Iijima K, Eto M, Ouchi Y (2008) Mechanism of pi-induced vascular calcification. J Atheroscler Thromb 15: 63-68.
39. Peters F, Epple M (2001) Simulating arterial wall calcification in vitro: biomimetic crystallization of calcium phosphates under controlled conditions. Z Kardiol 90 Suppl 3: 81-85. (Pubitemid 32291171)
40. Hamad M, Heughebaert J-C (1986) The growth of whitlockite. Journal of Crystal Growth 79: 192-197. doi:10.1016/0022-0248(86)90435-5.
41. Lagier R, Baud CA (2003) Magnesium whitlockite, a calcium phosphate crystal of special interest in pathology. Pathol Res Pract 199: 329-335. doi:10.1078/0344-0338-00425. (Pubitemid 36939584)
42. Verberckmoes SC, Persy V, Behets GJ, Neven E, Hufkens A, et al. (2007) Uremia-related vascular calcification: more than apatite deposition. Kidney Int 71: 298-303. doi:10.1038/sj.ki.5002028. (Pubitemid 46227088)
43. He Y, Yao G, Savoia C, Touyz RM (2005) Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. Circ Res 96: 207-215. doi:10.1161/01.RES. 0000152967.88472.3e. (Pubitemid 40209368)
44. Paravicini TM, Chubanov V, Gudermann T (2012) TRPM7: a unique channel involved in magnesium homeostasis. Int J Biochem Cell Biol 44: 1381-1384. doi:10.1016/j.biocel.2012.05.010.
45. Cao G, Thébault S, van der Wijst J, van der Kemp A, Lasonder E, et al. (2008) RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha-kinase domain. Curr Biol 18: 168-176. doi:10.1016/j.cub.2007.12.058.
46. Lee K-M, Kang H-A, Park M, Lee H-Y, Choi H-R, et al. (2012) Interleukin-24 attenuates β-glycerophosphate-induced calcification of vascular smooth muscle cells by inhibiting apoptosis, the expression of calcification and osteoblastic markers, and the Wnt/β-catenin pathway. Biochem Biophys Res Commun 428: 50-55. doi:10.1016/j.bbrc.2012.09.145.
47. Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, et al. (2006) Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 79: 431-442. doi:10.1007/s00223-006-0126-z. (Pubitemid 46020455)
48. Maruyama T, Kanaji T, Nakade S, Kanno T, Mikoshiba K (1997) 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. J Biochem 122: 498-505. (Pubitemid 27443223)
49. Harteneck C, Gollasch M (2011) Pharmacological modulation of diacylglycerol-sensitive TRPC3/6/7 channels. Curr Pharm Biotechnol 12: 35-41.